Newsroom

NEW YORK--(BUSINESS WIRE)--Stable Asset Management (“Stable”), one of the largest and most-tenured GP stake builders focused on GP seed and acceleration investing, today announced the completion of its sale of a portfolio of minority, net revenue-share interests in alternative asset managers (the “Target Portfolio”) to Navigator Global Investments (ASX: NGI), a diversified alternative asset management company, for a total consideration of $190 million. The closing marks the establishment of a l...

NEW YORK--(BUSINESS WIRE)--CSC Investments II LLC, a Delaware limited liability company (“CSC Investments II”) and a wholly owned subsidiary of Optimum Communications, Inc. (NYSE: OPTU) (“Optimum”), today announced the final results of its tender offer, which expired at 5:00 p.m., New York City time, on June 30, 2026. Based on the final count by Equiniti Trust Company, LLC, the depositary for the tender offer (the “Depositary”), a total of 246,605,915 shares of Optimum’s Class A Common Stock, p...

RALEIGH, N.C.--(BUSINESS WIRE)--Vontier Completes Divestiture of Teletrac Navman...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that its wholly owned subsidiary, FORUS Therapeutics Inc, has received a Notice of Compliance (NOC) authorizing BESREMi® (ropeginterferon alfa-2b) for the treatment of adults with polycythemia vera (PV). BESREMi® is expected to become commer...

RICHMOND, Va. & NEW YORK--(BUSINESS WIRE)--NSTA and Tuva announced an expanded partnership to co-facilitate professional learning that strengthens data literacy in science education....

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research an...

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement in response to Chairman and CEO Omid Farokhzad, M.D.’s July 1, 2026 proposal to acquire Seer: “For the first time, we agree with Dr. Farokhzad – Seer should not be a public company. Seer should b...

CHARLOTTE, N.C.--(BUSINESS WIRE)--Krispy Kreme, Inc. (NASDAQ: DNUT) (“Krispy Kreme” or the “Company”), today announced that it will issue its second quarter 2026 earnings results on Thursday, August 6, 2026. The results and related slide presentation will be available on the Company’s website at investors.krispykreme.com beginning at 6:45 AM Eastern Time. Management will host a conference call and webcast to discuss the results at 8:00 AM Eastern Time on the same day. To register for the confer...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...